U.S. Markets close in 2 hrs 36 mins

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
75.54+0.58 (+0.77%)
As of 1:24PM EDT. Market open.
People also watch
Full screen
Previous Close74.96
Bid75.64 x 100
Ask75.65 x 700
Day's Range74.75 - 75.88
52 Week Range63.76 - 82.10
Avg. Volume8,691,842
Market Cap98.7B
PE Ratio (TTM)7.98
Earnings DateN/A
Dividend & Yield2.08 (2.82%)
Ex-Dividend Date2017-06-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters58 minutes ago

    AbbVie to remain cautious on drug pricing, shares fall

    AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates. Abbvie CEO Richard Gonzalez said on Friday the company would continue to be "careful and conservative" about pricing, even though the drugmaker has already concluded negotiations with insurers for coverage of its Humira drug in 2017 and 2018. "I'd say even in this last cycle, we have been even a little more conservative than we have been in the past because this (drug pricing) has become such a heated topic in the United States," Gonzalez said.

  • 4 Drug Stocks in Focus this World Hepatitis Day
    Zacks4 hours ago

    4 Drug Stocks in Focus this World Hepatitis Day

    Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

  • Morningstar6 hours ago

    Gilead's HCV and HIV Drugs Support Wide Moat

    We don't think the current price accounts for the company's pipeline.